Kornimate/medical-research-clean huggingface dataset:
cerebral blood flow and ventilatory responses during sleep in normoxia and intermittent hypoxia

Conditions: Obstructive Sleep Apnea of Adult; Hypoxia, Brain; Sleep Apnea; Sleep Disorder; Stroke; Blood Pressure; Endothelial Dysfunction; Oxidative Stress

Summary: a prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).

the investigators will explore the relationship between changes in cerebral blood flow (cbf) and ventilatory chemoreflexes i.e. acute ventilatory response to hypoxia (ahvr) and acute hypercapnic ventilatory response (hcvr) before, during and after sleep under normoxic conditions and sleep accompanied by isocapnic intermittent hypoxia (ih) among healthy human study participants. a pharmacological intervention will be utilized to manipulate the cbf in a randomized order. the study participants will also be randomly assigned the order to sleep either under normoxia or ih exposure. the experiments will be separated from one another with an interval of sufficient drug and ih exposure washout period. the venous blood samples and urinary samples will be collected for the vascular biomarkers.

Eligibility criteria:
inclusion criteria: * healthy adults * 18 - 45 years of age * living in calgary for the past one year * have no medical condition or should not be taking any blood pressure medications. * the participant should not be lactose intolerant exclusion criteria: * cerebrovascular, cardio-respiratory, renal and metabolic diseases * bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease * pregnancy, obese and sleep-disordered breathing * drug allergies to non-steroidal anti-inflammatories * currently smoking
trial of da-epoch regimen for nhl with hlh

Conditions: NHL With Hemophagocytic Lymphohistiocytosis

Summary: the major purpose of this clinical study is to assess clinical outcome of dose-adjusted epoch regimen for patients with non-hodgkin's lymphoma(nhl)-associated hemophagocytic lymphohistiocytosis

lymphoma-associated hemophagocytic lymphohistiocytosis(la-hlh) has a high fatality rate and the worst outcome. the major cause of la-hlh is aggressive non-hodgkin's lymphoma(nhl), especially t/nkt cell lymphomas. until now, there is no recommended therapeutic schedule for this fatal disease. dose-adjusted(da) epoch (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) shows effective activity in patients with aggressive nhl, which also contains the critical drugs for hlh of hlh-94/04. the investigators therefore developed da-epoch regimen to treat non-hodgkin's lymphoma with hemophagocytic lymphohistiocytosis and assess its clinical outcome including safety and efficacy.

Eligibility criteria:
inclusion criteria: 1 .histologically confirmed non-hodgkin's lymphoma; 2. patients whose clinical findings satisfy either of hlh 2004 standard: 3. newly-diagnosed and untreated; 4. understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements. hlh2004 standard at least 5 criteria out of the following: fever ≥ 38.5 ℃ for ≥ 7 days; hepatosplenomegaly; cytopenias affecting ≥ 2 of 3 lineages in pb hb \< 9 g/l platelet \< 100 x 109 /l anc \< 1.0 x 109 /l; hypertriglyceridemia and/or hypofibrinogenemia (fasting triglycerides ≥ 265 mg/dl, fibrinogen ≤ 1.5 g/l); hemophagocytosis in bm or spleen or ln; low or absent nk-cell activity ( according to local laboratory reference); serum-ferritin ≥ 500 mcg/l ; soluble cd25(sil-2 receptor) ≥ 2,400 u/ml ; 3.new-diagnosed and untreated; 4.understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements. exclusion criteria 1. primary hlh; 2. hlh from rheumatic disorder (such as systemic lupus erythematosus, adult onset still disease, antiphospholipid antibody syndrome); 3. pregnancy (as determined by serum or urine test) or active breast feeding; 4. concomitant malignancy other than nhl and need to treat; 5. concomitant with other hematologic diseases (such as leukemia, hemophilia primary myelofibrosis) which investigators considered it unsuitable to be enrolled into this clinical trial; 6. any potential drug abuse, medical, psychological or social conditions which may disturb this investigation and assessment; 7. in any conditions which investigator considered ineligible for this study

Keywords: non-hodgkin's lymphoma hemophagocytic lymphohistiocytosis da-epoch rituximab
concurrent chemo-proton radiotherapy with or without resection and spacer insertion for loco-regional recurrence of previous irradiated rectal cancer

Conditions: Previously Irradiated Recurrent Rectal Cancer

Summary: the investigators conduct this study to evaluate the efficacy and adverse effect of salvage concurrent chemo-proton therapy (ccpt) with or without surgical resection in previously irradiated recurrent rectal cancer.

the obtaining of local control in previously irradiated recurrent rectal cancer is crucial for survival prolongation as well as quality of life of patients. but, it is not easy to get with surgery and/or conventional radiotherapy (rt) because of the limitation of rt dose. proton therapy has unique advantage showing superior dose distribution focusing tumor escaping surrounding normal tissues using "bragg-peak".

Eligibility criteria:
inclusion criteria: * previously diagnosed as rectal cancer and received curative intent treatment * diagnosed as recurrent rectal cancer either pathology or radiologic exam * discussed at tumor board and recommend proton therapy * previous history of pelvic area radiotherapy * eastern cooperative oncology group performance status of 0 to 2 * informed consent to present study * consent to contraception for 6 months during and after study participation * maintained bone marrow function ( absolute neutrophil count ≥ 1,2 \* 109/l, platelet count ≥ 100 \* 109/l) * maintained renal, hepatic function creatinine clearance ≥ 50 ml/minute total bilirubin ≥ 2.2 mg/dl alkaline phosphatase ≥ 192 u/l exclusion criteria: * pregnant and/or breastfeeding woman * less than 12 weeks of expected survival * uncontrolled active co-morbidity
high-flow nasal oxygen during rigid bronchoscopy under general anesthesia: a randomized controlled trial

Conditions: Foreign Bodies; Tumor; Stenosis Trachea; Bronchus Tumour

Summary: the aim of this study is to evaluate the effect of high-flow nasal cannula oxygen administration on apnea in patients undergoing general anesthesia with rigid bronchoscopy compared with standard anesthesia methods.


Eligibility criteria:
inclusion criteria: * 1. patients undergoing general anesthesia with stent placement or bougination, biopsy or removal of a foreign body or a mass through a rigid bronchoscope * 2. patients aged 19 or older who meet american society of anesthesiologists (asa) physical class 2-4 exclusion criteria: * 1. patients with dementia or cognitive impairment * 2. pregnant women * 3. patients undergoing extracorporeal membrane oxygenation (ecmo) * 4. patients with active nasal bleeding), severe nasal obstruction, recent nasal trauma of surgery * 5. patients with current maxillofacial trauma or basal skull fracture * 6. patients who had previously undergone rigid bronchoscopy / surgery * 7. if the subject includes a person who can not read the written consent (eg, illiterate, foreigner, etc.)
effects of neuromuscular training on functional capacity in acute coronary syndrome patients

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to analyse the effects of neuromuscular training on functional capacity in patients with acute coronary syndrome, compared to the classic strength training of the cardiac rehabilitation programs

so far, there are no previous studies that analyze the effects of neuromuscular training on functional capacity in patients with acute coronary syndrome. aim: the main objective of this study is to assess the effects of a 10 weeks neuromuscular training vs traditional strength training programme in patients with acute coronary syndrome. design: randomized clinical trial

Eligibility criteria:
inclusion criteria: * acute coronary syndrome patients * physical activity must have been prescribed exclusion criteria: * inflammatory cardiac disease * severe or moderate ventricular dysfunction * heart failure * severe arrhytmias * systemic hypertension \>95% percentile * pulmonary hypertension \>40 mmhg * aortic stenosis * baseline o2 \<90% * severe valve insufficiency

Keywords: acute coronary syndrome neuromuscular training cardiac rehabilitation functional capacity
regulation of blood dendritic cells during immune therapy for hymenoptera venom allergy

Conditions: Hymenoptera Venom Allergy

Summary: dendritic cells (dc) play a key role in the pathogenesis of allergic diseases. the regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.


Eligibility criteria:
inclusion criteria: * patients with diagnosed hymenoptera venom allergy * no previous treatments for hymenoptera venom allergy exclusion criteria: * treatment with immunosuppressive agents * any malignant disease * infections within 1 week prior to the initiation of the treatment

Keywords: hymenoptera venom allergy dendritic cells (dc)
confocal laser endomicroscopy with cresyl violet for in vivo diagnosis of gastric intestinal metaplasia

Conditions: Gastric Intestinal Metaplasia

Summary: confocal laser endomicroscopy (cle) is a novel endoscopic system which can provide approximately 1000-fold magnification of the gastrointestinal mucosa. previous studies have demonstrated its diagnostic value for gastric intestinal metaplasia (gim) with the use of a contrast agent.recently, cresyl violet (cv) has been used in cle to visualize tissue architecture in human ileum, colon or myenteric plexus.no investigation has reported the characterization of gim imaged with cle when using cv as staining dye


Eligibility criteria:
inclusion criteria: * patients who had long-lasting upper gastrointestinal symptoms and aged 40 years or above * patients with h. pylori infection, or known gim or atrophic gastritis exclusion criteria: * patients with a history of gi surgery * advanced gastric carcinoma or any other malignancy in the gi tract * acute upper gi bleeding * patients with contraindications to cle examination, such as coagulopathy, pregnancy, breast feeding, impaired renal or liver function * patients refused to provide informed consent
epicardial adipose tissue volume and attenuation in acute ischemic stroke

Conditions: Ischemic Stroke

Summary: excessive accumulation or abnormal distribution of adipose tissue is a recognized risk factor for ischemic stroke. however, the impact of overweight or obesity on clinical outcomes of ischemic stroke is uncertain. the proposition of obesity paradox in stroke patients makes secondary prevention ambiguous for patients with ischemic stroke and overweight or obesity. body mass index (bmi) or abdominal visceral fat area was used to measure obesity in previous studies. epicardial adipose tissue (eat) is a unique visceral fat, which has higher expression of proinflammatory genes than subcutaneous fat and abdominal visceral fat. and inflammation is closely related to the prognosis of ischemic stroke. in this study, the investigators assume eat volume or attenuation evaluated by chest computed tomography (ct) scan might affect the prognosis of patients with acute ischemic stroke (ais). patients with the first acute ischemic stroke will be stratified into tertile groups based on eat volume or attenuation. the primary endpoint measure is the proportion of patients with a favorable recovery of nerve function deficiency assessed by modified rankin scale （mrs≤2） at 90 days after the onset of symptoms. secondary endpoints include the following: the percentage of functional recovery measured by the barthel index (bi) at day 90 after stroke onset, the propotion of clinical improvement (with an improvement of ≥ 4 points on the national institute of health stroke scale score or the resolution of the neurologic deficit) or neurological deterioration (with a decline by ≥ 4 points in the total national institute of health stroke scale score) at day 7 after stroke onset, incidence of hemorrhagic transformation and mortality within 7 days of symptom onset.


Eligibility criteria:
inclusion criteria: * patient is between 18 and 80 years of old; * acute ischemic stroke（ais）is diagnosed by brain imaging, and this is the first ischemic stroke event; * patient is admitted to hospital within 72 hours after stroke onset; * modified rankin scale score (mrs) ≤2 before onset; * patient undergoes chest ct scanning during hospitalization; * provision of written informed consent. exclusion criteria: * pregnant or nursing women; * complicated with cerebral hemorrhage showed by cranial ct on admission; * patient had brain tumor, intracranial aneurysm, arteriovenous malformation, or cerebral hemorrhage or underwent brain surgery in the past; * severe cardiac, liver, pulmonary, or kidney disease, malignancy, severe coagulation dysfunction, and systemic organ dysfunction; * failure to accomplish 7-day and 3-month follow up.

Keywords: ischemic stroke epicardial adipose tissue obesity
oxford partial knee kinematics gait analysis study

Conditions: Medial Knee Compartment Arthritis

Summary: the objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (uka), using the oxford partial knee, versus normal knee.


Eligibility criteria:
inclusion criteria: * patients with medial knee compartment arthritis exclusion criteria: * patients with diagnoses other than osteoarthritis (i.e., rheumatoid arthritis, psoriatic arthritis, etc.) * patients with significant diseases of other joints of the lower extremity * patients with a diagnosed disorder with gait disturbance (e.g. lower extremity weakness, prior lower extremity arthrodesis, diagnosed movement disorders, etc.).

Keywords: partial knee arthroplasty
optical coherence tomography-guided coronary intervention in patients with complex lesions: a randomized controlled trial (occupi trial)

Conditions: Coronary Artery Disease

Summary: there is no definite conclusive work about the benefit of oct-guided pci, which should be determined in complex pci, assuming better stent optimization by oct. in the study, we will explore the clinical implication of oct-guided pci of complex lesions.

eligible patients will be randomly assigned to either oct-guided pci arm and angiography-guided pci with routine high pressure nc ballooning arm in 1:1 ratio. within oct-guided pci arm, the use of oct will be also assigned to full oct-guidance arm and postprocedural oct only arm. and comparison of stent implantation with and without preprocedural oct will be evaluated by postprocedural oct (oct-defined stent optimization will be assessed). in angiography-guided pci arm, pci for complex lesion will be performed without guidance of intravascular imaging, and routine use of high pressure postdilation with nc balloon will be also recommended. primary endpoint will be evaluated during 12 months after pci.

Eligibility criteria:
inclusion criteria * age 19-85 years * patients with ischemic heart diseases (including stable angina, unstable angina and acute myocardial infarction) presented with typical chest pain or objective evidences of myocardial ischemia (positive invasive or non-invasive studies, electrocardiogram (ecg) consistent with ischemia, or elevated cardiac enzymes) * complex coronary stenotic lesions (\>50% based on visual estimate) considered for coronary revascularization with des * definition of complex lesions (at least one): * acute myocardial infarction * chronic total occlusion * long lesion: expected stent length ≥28mm based on angiographic estimation * calcified lesion * bifurcation (including all techniques, one- or two-stent) * unprotected left main disease * small vessel diseases with reference vessel diameter less than 2.5 mm * intracoronary thrombus visible on the angiography * stent thrombosis * in-stent restenosis * bypass graft lesion * patients who provide signed informed consent exclusion criteria * severe hepatic dysfunction (≥3 times normal reference values) * significant renal dysfunction (serum creatinine \>2.0 mg/dl) * platelet count \ 700,000 cells/mm3, a white blood cell count of \<3,000 cells/mm3, hemoglobin \<8.0 g/dl, or other known bleeding diathesis * hemodynamically unstable during procedures or cardiogenic shock * pregnant women or women who might be pregnant * life expectancy; less than 1 year * inability to understand or read the informed content

Keywords: coronary artery disease optical coherence tomography antiplatelet therapy
evaluation of c-reactive protein level in the group of patient with pain form of temporomandibular joint dysfunction

Conditions: Temporomandibular Joint Disorders

Summary: temporomandibular joints dysfunction is a functional disorder concern with the abnormal functioning of the muscles of the stomatognathic system, temporomandibular joints involved in the dynamic movements of the jaw and surrounding structures. the aim of the study was to compare the level of c-reactive protein in patients with pain and painless form of temporomandibular joints dysfunction.

temporomandibular joints dysfunction is a functional disorder concern with the abnormal functioning of the muscles of the stomatognathic system, temporomandibular joints involved in the dynamic movements of the jaw and surrounding structures. the aim of the study was to compare the level of c-reactive protein in patients with pain and painless form of temporomandibular joints dysfunction. material and methods the research material consisted of 72 patients who reported to the prosthetic treatment because of temporomandibular joint dysfunction. the study group included 36 patients with pain form of dysfunction, and control group - 36 patients with painless form of disorder. each patient underwent specialized examination of functional disorders, in order to diagnose the type of dysfunction and commissioned to carry out a study of the blood test concern with evaluation of the c-reactive protein (crp) level in the same analytical laboratory. the results of the investigation were subjected to statistical analysis.

Eligibility criteria:
inclusion criteria: * factors of inclusion in the study are: pain form of temporomandibular joints dysfunction, the required age range, a good general state of health (particularly with regard to cardiac and metabolic disorders). exclusion criteria: * factors for exclusion from the research include: the will of the patient, the emergence of general diseases, trauma, or local inflammation.
the bravado registry

Conditions: ACS - Acute Coronary Syndrome; Oncology

Summary: the bravado registry pretends to identify stratification, diagnosis, total atherosclerotic burden and treatment approaches in oncologic patients with acute coronary syndrome (acs) and identify strategies to improve health care quality


Eligibility criteria:
inclusion criteria: * definitive cancer diagnosis - biopsy * acute coronary syndrome - requiring urgent invasive risk stratification exclusion criteria: * kps \ / 3 * life expectancy less 24hs * end of life care * lack of consistent record data

Keywords: cardio-oncology interventional cardiology cancer oncology acute coronary syndrome myocardial infarction
prevention of cardiovascular disease using a single polypill in an urban population - focus on liver-related variables.

Conditions: Cardiovascular Diseases

Summary: the primary purpose of this study is to determine the effects of a fixed dose combination of valsartan, hydrochlorothiazide, atorvastatin and aspirin (polypill) on prevention of cardiovascular events in adults older than 50. various liver-related variables will also be recorded which will allow studying the effects of polypill on the liver and the effect of liver diseases such as nonalcoholic steatohepatitis on cardiovascular events and the protective effect of polypill.

2400 subjects will be randomly selected from participants of the golestan cohort study (gcs) who are living in gonbad and are over 50 years old. these subjects will be randomized to either receive polypill or no treatment. those agreeing to the study will undergo additional measurements (in addition to the baseline measurements performed in the gcs) including liver-related tests such as liver enzyme levels, abdominal ultrasonography and liver stiffness measurement. some additional tests such as color doppler ultrasonography of carotid vessels will also be performed. subjects in the polypill arm who have no contraindication for the components of the pill will receive a single daily dose of polypill for 5 years.

Eligibility criteria:
inclusion criteria: - being enrolled in golestan cohort study exclusion criteria: * debilitating disease causing inability to comply * contraindications to any of the components of polypill * not consenting to the study

Keywords: atorvastatin aspirin nonalcoholic steatohepatitis nonalcoholic fatty liver disease antihypertensive agents
telemonitoring system study in participants with type 2 diabetes mellitus (mk-0000-347)

Conditions: Type 2 Diabetes Mellitus

Summary: the primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback to the general practitioner, can improve metabolic control and overall cardiovascular risk in individuals with type 2 diabetes mellitus (t2dm), as compared to usual practice.


Eligibility criteria:
inclusion criteria: * has type 2 diabetes * treated with oral agents in monotherapy or combined therapy ± basal insulin * previously educated to self-monitoring blood glucose (smbg) use exclusion criteria: * has type 2 diabetes non-pharmacologically treated * has type 2 diabetes treated with multiple daily injections of insulin * is unable to use the telemedicine system * pregnancy * has major cardiovascular, cerebrovascular, or peripheral vascular event in the last 6 months * has any disease or condition, including alcohol or drugs abuse, that may interfere with study completion
effect of oasis® wound matrix on stage iii and iv trunk pressure wounds treated with negative pressure wound therapy

Conditions: Open Wound Abdominal Wall; Wound Non Healing

Summary: this study evaluates the therapeutic effect of oasis® matrix along with negative pressure wound therapy (npwt) on pressure wounds. either oasis or standard foam will be applied to the wound prior to activating the npwt.

in this study, patients being treated with negative pressure wound therapy (npwt) will be randomized to receive either: 1. oasis® matrix, applied to the wound, along with standard of care including npwt or 2. standard foam, applied to the wound prior to activation of npwt, which is standard care. wounds will be examined weekly for up to 12 weeks. at weeks 4, 8, and 12, the npwt evacuation canister will be collected for specimen analysis. the aim of this study is to determine the therapeutic effect of using oasis® wound matrix with npwt. outcomes include: a) closure rate of non-healing wounds, and b) levels of growth factors and interleukins in fluid evacuated from the wound.

Eligibility criteria:
inclusion criteria: * adults aged 18-89 who exhibit stage iii or iv trunk pressure wounds with no signs of infection. * hba1c \< 8 (if patient is diabetic) * adequate nutrition including albumin above 2.0 and prealbumin above 15. exclusion criteria: * wounds that cannot have a npwt device properly applied due to location (too close to anus), diarrhea, periwound skin issues. * patients with infected wounds.